Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
Meschiari M, Faltoni M, Kaleci S, Tassoni G, Orlando G, Franceschini E, Burastero G, Bedini A, Serio L, Biagioni E, Melegari G, Venturelli C, Sarti M, Bertellini E, Girardis M, Mussini C. Meschiari M, et al. Among authors: faltoni m. Int J Antimicrob Agents. 2024 May;63(5):107134. doi: 10.1016/j.ijantimicag.2024.107134. Epub 2024 Mar 5. Int J Antimicrob Agents. 2024. PMID: 38453094
Quality of life and intrinsic capacity in patients with post-acute COVID-19 syndrome is in relation to frailty and resilience phenotypes.
Guaraldi G, Milic J, Barbieri S, Marchiò T, Caselgrandi A, Motta F, Beghè B, Verduri A, Belli M, Gozzi L, Iadisernia V, Faltoni M, Burastero G, Dessilani A, Del Monte M, Dolci G, Bacca E, Franceschi G, Yaacoub D, Volpi S, Mazzochi A, Clini E, Mussini C. Guaraldi G, et al. Among authors: faltoni m. Sci Rep. 2023 Jun 2;13(1):8956. doi: 10.1038/s41598-023-29408-z. Sci Rep. 2023. PMID: 37268716 Free PMC article.
Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study.
Mussini C, Cozzi-Lepri A, Meschiari M, Franceschini E, Burastero G, Faltoni M, Franceschi G, Iadisernia V, Volpi S, Dessilani A, Gozzi L, Conti J, Del Monte M, Milic J, Borghi V, Tonelli R, Brugioni L, Romagnoli E, Pietrangelo A, Corradini E, Girardis M, Busani S, Cossarizza A, Clini E, Guaraldi G. Mussini C, et al. Among authors: faltoni m. Viruses. 2023 Jan 20;15(2):294. doi: 10.3390/v15020294. Viruses. 2023. PMID: 36851508 Free PMC article.
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients.
Alteri C, Fox V, Scutari R, Burastero GJ, Volpi S, Faltoni M, Fini V, Granaglia A, Esperti S, Gallerani A, Costabile V, Fontana B, Franceschini E, Meschiari M, Campana A, Bernardi S, Villani A, Bernaschi P, Russo C, Guaraldi G, Mussini C, Perno CF. Alteri C, et al. Among authors: faltoni m. Commun Biol. 2022 Dec 15;5(1):1376. doi: 10.1038/s42003-022-04322-8. Commun Biol. 2022. PMID: 36522489 Free PMC article.
Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature.
Burastero GJ, Orlando G, Santoro A, Menozzi M, Franceschini E, Bedini A, Cervo A, Faltoni M, Bacca E, Biagioni E, Coloretti I, Melegari G, Maccieri J, Busani S, Bertellini E, Girardis M, Ferrarini G, Rofrano L, Sarti M, Mussini C, Meschiari M. Burastero GJ, et al. Among authors: faltoni m. Antibiotics (Basel). 2022 Jul 26;11(8):1007. doi: 10.3390/antibiotics11081007. Antibiotics (Basel). 2022. PMID: 35892396 Free PMC article.
First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy.
Meschiari M, Cozzi-Lepri A, Tonelli R, Bacca E, Menozzi M, Franceschini E, Cuomo G, Bedini A, Volpi S, Milic J, Brugioni L, Romagnoli E, Pietrangelo A, Corradini E, Coloretti I, Biagioni E, Busani S, Girardis M, Cossarizza A, Clini E, Guaraldi G, Mussini C; Modena COVID-19 Working Group (MoCo19). Meschiari M, et al. BMJ Open. 2022 Jan 3;12(1):e054069. doi: 10.1136/bmjopen-2021-054069. BMJ Open. 2022. PMID: 34980623 Free PMC article.
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections.
Meschiari M, Volpi S, Faltoni M, Dolci G, Orlando G, Franceschini E, Menozzi M, Sarti M, Del Fabro G, Fumarola B, Guarneri F, Lanza P, Lorenzotti S, Saccani B, Signorini L, Van Hauwermeiren E, Gatti M, Pea F, Castelli F, Mussini C. Meschiari M, et al. Among authors: faltoni m. JAC Antimicrob Resist. 2021 Dec 11;3(4):dlab188. doi: 10.1093/jacamr/dlab188. eCollection 2021 Dec. JAC Antimicrob Resist. 2021. PMID: 34909691 Free PMC article.
The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study.
Milic J, Banchelli F, Meschiari M, Franceschini E, Ciusa G, Gozzi L, Volpi S, Faltoni M, Franceschi G, Iadisernia V, Yaacoub D, Dolci G, Bacca E, Rogati C, Tutone M, Burastero G, Raimondi A, Menozzi M, Cuomo G, Corradi L, Orlando G, Santoro A, Digaetano M, Puzzolante C, Carli F, Bedini A, Busani S, Girardis M, Cossarizza A, Miglio R, Mussini C, Guaraldi G, D'Amico R. Milic J, et al. Among authors: faltoni m. PLoS One. 2021 Aug 12;16(8):e0251378. doi: 10.1371/journal.pone.0251378. eCollection 2021. PLoS One. 2021. PMID: 34383784 Free PMC article.
18 results